Rongchang Biotech: The first patient has been enrolled in the clinical study of RC148 combined with first-line chemotherapy for unresectable or metastatic stage II/III colorectal cancer.

On June 15, Rongchang Biotechnology announced that the Phase II/III clinical study of the company's independently developed novel bispecific antibody drug RC148 in combination with first-line chemotherapy for unresectable or metastatic colorectal cancer has successfully completed dosing for the first patient enrolled. This study is a randomized, multicenter Phase II/III clinical trial aimed at evaluating the efficacy and safety of RC148 in combination with first-line chemotherapy for unresectable or metastatic colorectal cancer.